Deutsche Bank Closes Catalyst Call on International Flavors & Fragrances (IFF)
Get Alerts IFF Hot Sheet
Rating Summary:
23 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 10 | New: 23
Join SI Premium – FREE
Deutsche Bank analyst David Begleiter reiterated a Buy rating and $90.00 price target on International Flavors & Fragrances (NYSE: IFF)
The analyst comments "We are closing our short-term Buy catalyst call on IFF as the catalyst events we identified (the sale of Pharma Solutions for $3.1B or a formal announcement that a sale process for Pharma Solutions was underway in conjunction with the Q4 earnings release) did not occur. Instead, IFF announced that it has decided to cut its quarterly dividend (of $0.80/share) by 50% (to $0.40/share) to help enable faster deleveraging of its balance sheet. While disappointing, IFF stated on the Q4 earnings conference call that it "continues to work on additional divestitures" and remains confident it will achieve its net debt-to-EBITDA target of <3x (versus 4.7x at 12/30/23). Although IFF would not commit to achieving this target by year-end '24, we still believe a sale of Pharma Solutions will likely be announced in the near future as portfolio optimization actions to improve the balance sheet are the top priority for new CEO Erik Fyrwald. With deleveraging underway, actions being taken to improve the underlying business, consumer demand trending favorably and valuation an attractive 14.5x '24E EBITDA versus 17.1x for Ingredients peers (with 1x = $8/shr, or 10% of the current share price), we reiterate our Buy rating."
For an analyst ratings summary and ratings history on International Flavors & Fragrances click here. For more ratings news on International Flavors & Fragrances click here.
Shares of International Flavors & Fragrances closed at $76.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal
- Worried the AI trade has gone too far? Evercore likes these 4 stocks
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
Deutsche Bank, Earnings, Deustche Bank Catalyst CallSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share